Department of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Department of Clinical Laboratory, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Medicine (Baltimore). 2022 Aug 19;101(33):e30070. doi: 10.1097/MD.0000000000030070.
Ecthyma gangrenosum (EG) is a potentially life-threatening, systemic infection generally caused by Pseudomonas aeruginosa. Data on EG caused by Staphylococcus aureus in patients with hematological malignancies are scarce. The present case report aimed to describe the clinical features of EG caused by S. aureus in patients with hematological malignancies and to provide a comprehensive review of previous studies on the topic.
The first patient was a 61-year-old man with acute myeloid leukemia who presented fever and multiple lesions during chemotherapy. The second patient was a 47-year-old man with myelodysplastic syndrome who developed progressive erythematous necrotic plaques on his extremities and face.
Both cases were diagnosed as EG caused by S. aureus. While the first patient had concurrent methicillin-resistant S. aureus (MRSA) bacteremia, the second patient had positive results only for tissue culture of the skin lesion isolated methicillin-sensitive S. aureus.
Vancomycin was initiated with critical care to the first patient. Cefazolin was administered to the second patient for 3 weeks, followed by cephalexin for 1 week.
The first patient died of a brain hemorrhage and multiple organ failure. The second patient was cured without relapse.
Of 18 patients in the previous and current studies with EG caused by S. aureus, 6 (33%) had an underlying hematological malignancy, and 10 (56%) had EG caused by MRSA. While 28% of the patients had positive blood cultures, all tissue cultures were positive. All 3 fatalities had concurrent bacteremia (MRSA caused two). EG caused by MRSA with concurrent bacteremia can be fatal, especially in patients with hematological malignancies. Although S. aureus-associated EG in patients with hematological malignancies is relatively uncommon, tissue cultures with an initial gram stain smear are essential for selecting appropriate empirical antimicrobials, including the coverage of S. aureus.
坏疽性脓皮病(EG)是一种潜在危及生命的全身性感染,通常由铜绿假单胞菌引起。有关血液恶性肿瘤患者金黄色葡萄球菌引起的 EG 的数据很少。本病例报告旨在描述血液恶性肿瘤患者金黄色葡萄球菌引起的 EG 的临床特征,并对该主题的以往研究进行全面回顾。
第一位患者是一名 61 岁男性,患有急性髓系白血病,在化疗期间出现发热和多处病变。第二位患者是一名 47 岁男性,患有骨髓增生异常综合征,四肢和面部出现进行性红斑坏死斑块。
两位患者均被诊断为金黄色葡萄球菌引起的 EG。第一位患者同时患有耐甲氧西林金黄色葡萄球菌(MRSA)菌血症,而第二位患者仅对皮肤病变的组织培养呈阳性,分离出甲氧西林敏感的金黄色葡萄球菌。
对第一位患者给予万古霉素治疗,并进行重症监护。第二位患者接受头孢唑林治疗 3 周,然后改用头孢氨苄治疗 1 周。
第一位患者死于脑出血和多器官衰竭。第二位患者治愈后无复发。
在之前和当前的 18 项研究中,有 6 例(33%)患有血液恶性肿瘤的患者患有金黄色葡萄球菌引起的 EG,有 10 例(56%)患有由 MRSA 引起的 EG。尽管 28%的患者血液培养呈阳性,但所有组织培养均呈阳性。所有 3 例死亡患者均合并菌血症(MRSA 引起 2 例)。合并菌血症的 MRSA 引起的 EG 可能致命,尤其是在血液恶性肿瘤患者中。虽然血液恶性肿瘤患者金黄色葡萄球菌相关性 EG 相对少见,但初始革兰氏染色涂片的组织培养对于选择合适的经验性抗菌药物至关重要,包括覆盖金黄色葡萄球菌。